Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Immunomedics Inc (NASDAQ:IMMU)

2.16
Delayed Data
As of Aug 28
 +0.20 / +10.20%
Today’s Change
1.69
Today|||52-Week Range
5.48
-55.00%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$185.4M

Company Description

Immunomedics, Inc. is a biopharmaceutical company, which engages in the business of researching, developing, manufacturing and marketing biopharmaceutical products. The company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. It markets and sells its products in the U.S. and throughout Europe. Immunomedics was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ.

Contact Information

Immunomedics, Inc.
300 The American Road
Morris Plains New Jersey 07950
P:(973) 605-8200
Investor Relations:

Employees

Shareholders

Individual stakeholders7.59%
Mutual fund holders26.26%
Other institutional18.60%

Top Executives

David M. GoldenbergChairman, Chief Scientific & Patent Officer
Cynthia L. SullivanPresident, Chief Executive Officer & Director
Peter P. PfreundschuhChief Financial Officer & Vice President-Finance
Phyllis ParkerSecretary